nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—Postnasal drip—Varenicline—nicotine dependence	0.053	0.0754	CcSEcCtD
Aprepitant—Upper-airway cough syndrome—Varenicline—nicotine dependence	0.0449	0.0639	CcSEcCtD
Aprepitant—Enterocolitis—Varenicline—nicotine dependence	0.0296	0.042	CcSEcCtD
Aprepitant—Polydipsia—Varenicline—nicotine dependence	0.0265	0.0376	CcSEcCtD
Aprepitant—Sensory disturbance—Varenicline—nicotine dependence	0.0265	0.0376	CcSEcCtD
Aprepitant—Throat irritation—Varenicline—nicotine dependence	0.0163	0.0231	CcSEcCtD
Aprepitant—TACR3—Peptide GPCRs—OPRM1—nicotine dependence	0.0156	0.0572	CbGpPWpGaD
Aprepitant—TACR3—cardiovascular system—nicotine dependence	0.0136	0.557	CbGeAlD
Aprepitant—Upset stomach—Varenicline—nicotine dependence	0.0125	0.0178	CcSEcCtD
Aprepitant—Cyst—Varenicline—nicotine dependence	0.0123	0.0174	CcSEcCtD
Aprepitant—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.0122	0.0173	CcSEcCtD
Aprepitant—Laryngeal pain—Varenicline—nicotine dependence	0.012	0.0171	CcSEcCtD
Aprepitant—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.0119	0.0437	CbGpPWpGaD
Aprepitant—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0107	0.0394	CbGpPWpGaD
Aprepitant—Glycosuria—Varenicline—nicotine dependence	0.0101	0.0144	CcSEcCtD
Aprepitant—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00976	0.0359	CbGpPWpGaD
Aprepitant—Chest discomfort—Varenicline—nicotine dependence	0.00927	0.0132	CcSEcCtD
Aprepitant—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00908	0.0129	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00887	0.0326	CbGpPWpGaD
Aprepitant—Dysarthria—Varenicline—nicotine dependence	0.00867	0.0123	CcSEcCtD
Aprepitant—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00858	0.0316	CbGpPWpGaD
Aprepitant—Musculoskeletal pain—Varenicline—nicotine dependence	0.0083	0.0118	CcSEcCtD
Aprepitant—Pulmonary embolism—Varenicline—nicotine dependence	0.00821	0.0117	CcSEcCtD
Aprepitant—Blood pressure increased—Varenicline—nicotine dependence	0.00821	0.0117	CcSEcCtD
Aprepitant—Eructation—Varenicline—nicotine dependence	0.00806	0.0115	CcSEcCtD
Aprepitant—Salivary hypersecretion—Varenicline—nicotine dependence	0.00797	0.0113	CcSEcCtD
Aprepitant—TACR1—Peptide GPCRs—OPRM1—nicotine dependence	0.0076	0.0279	CbGpPWpGaD
Aprepitant—Urine output increased—Varenicline—nicotine dependence	0.00742	0.0105	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00732	0.0269	CbGpPWpGaD
Aprepitant—Euphoric mood—Varenicline—nicotine dependence	0.00705	0.01	CcSEcCtD
Aprepitant—Diabetes mellitus—Varenicline—nicotine dependence	0.00685	0.00973	CcSEcCtD
Aprepitant—Polyuria—Varenicline—nicotine dependence	0.00678	0.00964	CcSEcCtD
Aprepitant—TACR3—brain—nicotine dependence	0.0067	0.273	CbGeAlD
Aprepitant—Disorientation—Varenicline—nicotine dependence	0.00666	0.00946	CcSEcCtD
Aprepitant—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00664	0.0244	CbGpPWpGaD
Aprepitant—Hot flush—Varenicline—nicotine dependence	0.00637	0.00905	CcSEcCtD
Aprepitant—Menopausal symptoms—Varenicline—nicotine dependence	0.00631	0.00897	CcSEcCtD
Aprepitant—Thirst—Varenicline—nicotine dependence	0.00626	0.0089	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00613	0.0225	CbGpPWpGaD
Aprepitant—Lethargy—Varenicline—nicotine dependence	0.00608	0.00864	CcSEcCtD
Aprepitant—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00605	0.0222	CbGpPWpGaD
Aprepitant—Osteoarthritis—Varenicline—nicotine dependence	0.00596	0.00847	CcSEcCtD
Aprepitant—Abdominal pain upper—Varenicline—nicotine dependence	0.00544	0.00773	CcSEcCtD
Aprepitant—Hypokalaemia—Varenicline—nicotine dependence	0.00542	0.00771	CcSEcCtD
Aprepitant—Breast disorder—Varenicline—nicotine dependence	0.00538	0.00765	CcSEcCtD
Aprepitant—Cramp muscle—Varenicline—nicotine dependence	0.00536	0.00762	CcSEcCtD
Aprepitant—Gastritis—Varenicline—nicotine dependence	0.00527	0.00749	CcSEcCtD
Aprepitant—Abdominal distension—Varenicline—nicotine dependence	0.00518	0.00737	CcSEcCtD
Aprepitant—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00517	0.019	CbGpPWpGaD
Aprepitant—Dysphagia—Varenicline—nicotine dependence	0.00515	0.00732	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00501	0.0184	CbGpPWpGaD
Aprepitant—Abdominal discomfort—Varenicline—nicotine dependence	0.00494	0.00701	CcSEcCtD
Aprepitant—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00493	0.0181	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00491	0.018	CbGpPWpGaD
Aprepitant—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00487	0.0179	CbGpPWpGaD
Aprepitant—Pollakiuria—Varenicline—nicotine dependence	0.00476	0.00676	CcSEcCtD
Aprepitant—Photosensitivity reaction—Varenicline—nicotine dependence	0.0047	0.00668	CcSEcCtD
Aprepitant—Weight increased—Varenicline—nicotine dependence	0.00468	0.00666	CcSEcCtD
Aprepitant—Hyperglycaemia—Varenicline—nicotine dependence	0.00464	0.0066	CcSEcCtD
Aprepitant—Infestation—Varenicline—nicotine dependence	0.00459	0.00652	CcSEcCtD
Aprepitant—Infestation NOS—Varenicline—nicotine dependence	0.00459	0.00652	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00455	0.00647	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—TAS2R16—nicotine dependence	0.00455	0.0167	CbGpPWpGaD
Aprepitant—Acute coronary syndrome—Varenicline—nicotine dependence	0.00452	0.00643	CcSEcCtD
Aprepitant—Myocardial infarction—Varenicline—nicotine dependence	0.0045	0.0064	CcSEcCtD
Aprepitant—Stomatitis—Varenicline—nicotine dependence	0.00447	0.00636	CcSEcCtD
Aprepitant—Conjunctivitis—Varenicline—nicotine dependence	0.00446	0.00634	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00433	0.0159	CbGpPWpGaD
Aprepitant—Bradycardia—Varenicline—nicotine dependence	0.00419	0.00596	CcSEcCtD
Aprepitant—Hypoaesthesia—Varenicline—nicotine dependence	0.0041	0.00583	CcSEcCtD
Aprepitant—Hallucination—Varenicline—nicotine dependence	0.0041	0.00583	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00409	0.015	CbGpPWpGaD
Aprepitant—Urinary tract disorder—Varenicline—nicotine dependence	0.00407	0.00578	CcSEcCtD
Aprepitant—Connective tissue disorder—Varenicline—nicotine dependence	0.00405	0.00576	CcSEcCtD
Aprepitant—Urethral disorder—Varenicline—nicotine dependence	0.00404	0.00574	CcSEcCtD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.004	0.0147	CbGpPWpGaD
Aprepitant—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00399	0.0147	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—FGD1—nicotine dependence	0.00393	0.0145	CbGpPWpGaD
Aprepitant—Erythema multiforme—Varenicline—nicotine dependence	0.0039	0.00554	CcSEcCtD
Aprepitant—Eye disorder—Varenicline—nicotine dependence	0.00385	0.00547	CcSEcCtD
Aprepitant—Tinnitus—Varenicline—nicotine dependence	0.00384	0.00546	CcSEcCtD
Aprepitant—Cardiac disorder—Varenicline—nicotine dependence	0.00382	0.00544	CcSEcCtD
Aprepitant—Angiopathy—Varenicline—nicotine dependence	0.00374	0.00531	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—OPRM1—nicotine dependence	0.00374	0.0137	CbGpPWpGaD
Aprepitant—Immune system disorder—Varenicline—nicotine dependence	0.00372	0.00529	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00372	0.0137	CbGpPWpGaD
Aprepitant—Mediastinal disorder—Varenicline—nicotine dependence	0.00371	0.00528	CcSEcCtD
Aprepitant—Chills—Varenicline—nicotine dependence	0.0037	0.00526	CcSEcCtD
Aprepitant—Mental disorder—Varenicline—nicotine dependence	0.00361	0.00513	CcSEcCtD
Aprepitant—Malnutrition—Varenicline—nicotine dependence	0.00359	0.0051	CcSEcCtD
Aprepitant—Erythema—Varenicline—nicotine dependence	0.00359	0.0051	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00357	0.0131	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—FGD1—nicotine dependence	0.00357	0.0131	CbGpPWpGaD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00356	0.0131	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00355	0.013	CbGpPWpGaD
Aprepitant—Flatulence—Varenicline—nicotine dependence	0.00353	0.00502	CcSEcCtD
Aprepitant—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00352	0.0129	CbGpPWpGaD
Aprepitant—Dysgeusia—Varenicline—nicotine dependence	0.00351	0.00499	CcSEcCtD
Aprepitant—Back pain—Varenicline—nicotine dependence	0.00347	0.00493	CcSEcCtD
Aprepitant—Muscle spasms—Varenicline—nicotine dependence	0.00345	0.0049	CcSEcCtD
Aprepitant—Tremor—Varenicline—nicotine dependence	0.00336	0.00478	CcSEcCtD
Aprepitant—Ill-defined disorder—Varenicline—nicotine dependence	0.00333	0.00473	CcSEcCtD
Aprepitant—Anaemia—Varenicline—nicotine dependence	0.00332	0.00471	CcSEcCtD
Aprepitant—Angioedema—Varenicline—nicotine dependence	0.00328	0.00466	CcSEcCtD
Aprepitant—Malaise—Varenicline—nicotine dependence	0.00323	0.0046	CcSEcCtD
Aprepitant—Syncope—Varenicline—nicotine dependence	0.00322	0.00457	CcSEcCtD
Aprepitant—Palpitations—Varenicline—nicotine dependence	0.00317	0.00451	CcSEcCtD
Aprepitant—Loss of consciousness—Varenicline—nicotine dependence	0.00315	0.00448	CcSEcCtD
Aprepitant—Cough—Varenicline—nicotine dependence	0.00313	0.00445	CcSEcCtD
Aprepitant—Convulsion—Varenicline—nicotine dependence	0.00311	0.00442	CcSEcCtD
Aprepitant—Hypertension—Varenicline—nicotine dependence	0.0031	0.0044	CcSEcCtD
Aprepitant—Myalgia—Varenicline—nicotine dependence	0.00305	0.00434	CcSEcCtD
Aprepitant—Arthralgia—Varenicline—nicotine dependence	0.00305	0.00434	CcSEcCtD
Aprepitant—Chest pain—Varenicline—nicotine dependence	0.00305	0.00434	CcSEcCtD
Aprepitant—Anxiety—Varenicline—nicotine dependence	0.00304	0.00433	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00303	0.00431	CcSEcCtD
Aprepitant—Discomfort—Varenicline—nicotine dependence	0.00302	0.00429	CcSEcCtD
Aprepitant—Dry mouth—Varenicline—nicotine dependence	0.00299	0.00425	CcSEcCtD
Aprepitant—Oedema—Varenicline—nicotine dependence	0.00293	0.00416	CcSEcCtD
Aprepitant—Infection—Varenicline—nicotine dependence	0.00291	0.00413	CcSEcCtD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00289	0.0106	CbGpPWpGaD
Aprepitant—Shock—Varenicline—nicotine dependence	0.00288	0.00409	CcSEcCtD
Aprepitant—Nervous system disorder—Varenicline—nicotine dependence	0.00287	0.00408	CcSEcCtD
Aprepitant—Thrombocytopenia—Varenicline—nicotine dependence	0.00287	0.00407	CcSEcCtD
Aprepitant—Tachycardia—Varenicline—nicotine dependence	0.00286	0.00406	CcSEcCtD
Aprepitant—Skin disorder—Varenicline—nicotine dependence	0.00284	0.00404	CcSEcCtD
Aprepitant—Hyperhidrosis—Varenicline—nicotine dependence	0.00283	0.00402	CcSEcCtD
Aprepitant—Anorexia—Varenicline—nicotine dependence	0.00279	0.00397	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00276	0.0101	CbGpPWpGaD
Aprepitant—Hypotension—Varenicline—nicotine dependence	0.00274	0.00389	CcSEcCtD
Aprepitant—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00272	0.01	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—DRD2—nicotine dependence	0.0027	0.00993	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TAS2R16—nicotine dependence	0.00269	0.00988	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00267	0.00379	CcSEcCtD
Aprepitant—Insomnia—Varenicline—nicotine dependence	0.00265	0.00376	CcSEcCtD
Aprepitant—Dyspnoea—Varenicline—nicotine dependence	0.00261	0.00371	CcSEcCtD
Aprepitant—Somnolence—Varenicline—nicotine dependence	0.0026	0.0037	CcSEcCtD
Aprepitant—TACR1—brain—nicotine dependence	0.00259	0.106	CbGeAlD
Aprepitant—Dyspepsia—Varenicline—nicotine dependence	0.00258	0.00366	CcSEcCtD
Aprepitant—Decreased appetite—Varenicline—nicotine dependence	0.00254	0.00362	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00253	0.00359	CcSEcCtD
Aprepitant—Fatigue—Varenicline—nicotine dependence	0.00252	0.00359	CcSEcCtD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00251	0.00924	CbGpPWpGaD
Aprepitant—Constipation—Varenicline—nicotine dependence	0.0025	0.00356	CcSEcCtD
Aprepitant—Pain—Varenicline—nicotine dependence	0.0025	0.00356	CcSEcCtD
Aprepitant—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00248	0.00912	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00245	0.009	CbGpPWpGaD
Aprepitant—Feeling abnormal—Varenicline—nicotine dependence	0.00241	0.00343	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0024	0.00881	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Varenicline—nicotine dependence	0.00239	0.0034	CcSEcCtD
Aprepitant—Urticaria—Varenicline—nicotine dependence	0.00233	0.00331	CcSEcCtD
Aprepitant—Body temperature increased—Varenicline—nicotine dependence	0.00231	0.00329	CcSEcCtD
Aprepitant—Abdominal pain—Varenicline—nicotine dependence	0.00231	0.00329	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00225	0.00828	CbGpPWpGaD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00223	0.00821	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00222	0.00817	CbGpPWpGaD
Aprepitant—Hypersensitivity—Varenicline—nicotine dependence	0.00216	0.00307	CcSEcCtD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00215	0.00789	CbGpPWpGaD
Aprepitant—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00212	0.00781	CbGpPWpGaD
Aprepitant—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00212	0.00779	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—OPRM1—nicotine dependence	0.00211	0.00777	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—FGD1—nicotine dependence	0.00211	0.00775	CbGpPWpGaD
Aprepitant—Asthenia—Varenicline—nicotine dependence	0.0021	0.00299	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00209	0.0077	CbGpPWpGaD
Aprepitant—Pruritus—Varenicline—nicotine dependence	0.00207	0.00294	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00204	0.00749	CbGpPWpGaD
Aprepitant—Diarrhoea—Varenicline—nicotine dependence	0.002	0.00285	CcSEcCtD
Aprepitant—Dizziness—Varenicline—nicotine dependence	0.00194	0.00275	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—FGD1—nicotine dependence	0.00192	0.00706	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—OPRM1—nicotine dependence	0.00192	0.00705	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKR1B10—nicotine dependence	0.00186	0.00685	CbGpPWpGaD
Aprepitant—Vomiting—Varenicline—nicotine dependence	0.00186	0.00265	CcSEcCtD
Aprepitant—Rash—Varenicline—nicotine dependence	0.00185	0.00262	CcSEcCtD
Aprepitant—Dermatitis—Varenicline—nicotine dependence	0.00184	0.00262	CcSEcCtD
Aprepitant—Headache—Varenicline—nicotine dependence	0.00183	0.00261	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—OPRM1—nicotine dependence	0.00183	0.00671	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—FGD1—nicotine dependence	0.00174	0.00641	CbGpPWpGaD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00174	0.0064	CbGpPWpGaD
Aprepitant—Nausea—Varenicline—nicotine dependence	0.00174	0.00247	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00173	0.00637	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00166	0.00609	CbGpPWpGaD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00164	0.00601	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00163	0.00599	CbGpPWpGaD
Aprepitant—CYP2C9—cardiovascular system—nicotine dependence	0.00156	0.0639	CbGeAlD
Aprepitant—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00154	0.00564	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—DRD2—nicotine dependence	0.00153	0.00561	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00151	0.00557	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—DRD2—nicotine dependence	0.00139	0.0051	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00134	0.00494	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—DRD2—nicotine dependence	0.00132	0.00485	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—WASF2—nicotine dependence	0.00131	0.00483	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TAS2R16—nicotine dependence	0.00131	0.00483	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00126	0.00463	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—WASF1—nicotine dependence	0.00126	0.00463	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00119	0.00436	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00117	0.0043	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00115	0.00422	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—OPRM1—nicotine dependence	0.00113	0.00417	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00108	0.00398	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00107	0.00392	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00103	0.00379	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—FGD1—nicotine dependence	0.00103	0.00379	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000981	0.00361	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—OPRM1—nicotine dependence	0.000937	0.00344	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000925	0.0034	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000912	0.00335	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKR1B10—nicotine dependence	0.00091	0.00335	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—DRD2—nicotine dependence	0.000819	0.00301	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000757	0.00278	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—DRD2—nicotine dependence	0.000746	0.00274	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000714	0.00262	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000704	0.00259	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—DRD2—nicotine dependence	0.000677	0.00249	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—WASF2—nicotine dependence	0.000641	0.00236	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—WASF1—nicotine dependence	0.000615	0.00226	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—OPRM1—nicotine dependence	0.000553	0.00203	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—DRD2—nicotine dependence	0.0004	0.00147	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000363	0.00134	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000263	0.000965	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000203	0.000746	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000185	0.00068	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000158	0.000581	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000122	0.000449	CbGpPWpGaD
